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As I sat writing this ‘personal reflections’ manuscript in the spring
of 2015, I was seeing press reports related to the use of tobacco
to make an Ebola therapeutic called ZMapp. For several months
newspaper articles, radio shows and hour-long TV documentaries
have given the public unprecedented exposure to the fact that
‘plant-made pharmaceuticals’ (PMP) can be life-saving drugs. I
have been asked by many nonspecialists – why tobacco? How can
this work? After spending over twenty years doing research in this
field and many, many hours in public policy meetings promoting
PMPs as an important tool of public health, I do not tire of hearing
the same questions. Although there is an increasing pipeline of
new protein drugs that will come from plants for both human and
animal health, the general public has little knowledge of these
specialized tools and therefore limited support for the field.
ZMapp has given us free advertising on an international scale that
I could never have anticipated.
On 4 August 2014, I opened an email from Larry Zeitlin – the
President of Mapp Biopharmaceutical, Inc. in San Diego, Califor-
nia, USA. It was a short message that alerted me to the fact that
ZMapp had been used to treat two missionaries in Liberia, and
they were recovering from severe Ebola infection. By that
afternoon, the newswires were alive with stories with titles such
as ‘Secret serum likely saved Ebola patients’. It was hardly a secret
to Larry and me, or our colleagues. Arizona State University (ASU)
had received substantial grant funds in 2002, including a
subcontract to our colleagues in San Diego. (Mapp Biopharma-
ceutical was incorporated the following year.) We had proposed
to the U.S. Army that plants (specifically tobacco) could be used
for rapid production of vaccines or monoclonal antibodies (mAbs)
that might be necessary to protect us from bioterrorism. This was
shortly after terrorist attacks on New York and the Pentagon in
2001, and the use of anthrax spores for a bioterror attack in the
U.S. Senate building; funding for countermeasures was quickly
becoming available. Our 2005 final report for the Army contract
ended with the statement: ‘we have demonstrated that Ebola
virus-specific “humanized” monoclonal antibodies can be pro-
duced using plant biotechnology’.
Research on our plant-made vaccines and mAbs for biodefence
has continued as collaborative programmes between Mapp and
ASU, gradually involving a wider range of multidisciplinary
participants. Chief among these were scientists at Kentucky
Bioprocessing LLC, founded in 2006, Herta Steinkellner and her
colleagues in Vienna who contributed host plant glycoengineer-
ing skills, Yuri Gleba and his colleagues at ICON Gentics and a
skilled team at the Army Medical Research Institute for Infectious
Diseases (USAMRIID) who conducted preclinical studies of our
Ebola-related products. Back-to-back ASU/Mapp publications in
2011 described our success in protecting animal models from
Ebola infection using plant-made vaccine or antibodies (Phool-
charoen et al., 2011; Zeitlin et al., 2011). Subsequent demon-
stration of protection of nonhuman primates using a cocktail of
three tobacco-made anti-Ebola mAbs as a postexposure thera-
peutic paved the way for ZMapp’s use in human volunteers. I am
sure all of us who participated even in some small part of ZMapp
development remain amazed that in only 12 years this project
could go from a hypothesis to a drug that is currently the leading
Ebola therapeutic under evaluation. We are also amazed this
happened with modest monetary support – only a fraction of
what is normally spent on development of a new drug in the
pharmaceutical industry. Early parts of my career had not seen
such clearly defined outcomes.
Events leading up to ‘Edible Vaccines’
The first half of my scientific career had been entirely devoted to
plant biology, with a strong interest in agricultural improvements
from a basic research perspective. I began with studies of
chloroplast structure and the factors which regulate/limit the
quantum efficiency of photosynthesis in higher plants. After
providing evidence that photosystems I and II exist in discrete
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polyprotein complexes, we were the first to show that proteins
are phosphorylated in plants – a newly emerging concept at that
time – and showed further that the kinase activation was
controlled by membrane redox potential – also a novel idea. This
phosphorylation altered chloroplast thylakoid surface charge and
thereby regulated spatial positioning of photosystem reaction
centres and light harvesting pigment–protein complexes to
modulate and optimize solar energy capture (Staehelin and
Arntzen, 1983). My studies of chloroplast membrane organiza-
tion led to a collaboration with agronomists who had discovered
herbicide-resistant weeds. Knowing that some of these herbicides
acted by blocking photosynthetic electron transport, my team
showed that triazine herbicides bind to a specific protein in the
photosystem II complex; this was the first molecular target known
for a commercial herbicide (Steinback et al., 1981). We learned
that a mutation of a single amino acid in this binding pocket could
completely block herbicide binding and action. This discovery was
at the time when genetic transformation was just being devel-
oped for plants, and our team was influential in pioneering the
concept of engineering a crop for herbicide resistance.
In 1984, I joined the DuPont Company to help create their
programme in crop biotechnology, with a strong focus on
creation of herbicide and insect resistance via introduction of new
proteins into the crop plants. This was my first intensive
interaction with scientists working at the forefront of gene
expression in plants. DuPont was also a setting where I could
learn the discipline needed for product development and man-
agement of multidisciplinary projects that have dominated my
research since that time.
While industrial research was one of the most enjoyable
periods of my research career, an offer from Texas A&M
University and the opportunity to lead their creation of a research
centre in the Texas Medical Center in Houston caused me to
again change directions. As the doors opened to this new
Institute, my goal was to find a project area that built upon my
prior expertise but which would have a very direct medical focus. I
was greatly influenced by the launch of The Children’s Vaccine
Initiative (CVI) in September of 1990 (Douglas, 1993). The CVI
purpose was to harness new technologies in the quest for the
ultimate vaccine – including being affordable, heat-stable and
orally administered candidates. This was the era when subunit
vaccines were just being accepted; in 1986, a vaccine to prevent
Hepatitis B infection was licensed in which the antigen was the
viral surface protein (HBsAg) produced in yeast using recombinant
DNA technology. This vaccine was very highly effective and a
dramatic breakthrough in vaccinology, but it was an injected
vaccine and still comparatively expensive. My prior experience in
DuPont made me ask – could plants make HBsAg? And next, to
ask whether it or other subunit antigens could be orally delivered?
While at Texas A&M, I had the wonderful good fortune to
meet Hugh S. Mason, who was a postdoc in Biochemistry. I was
and still am impressed by his skills in plant molecular biology.
Moreover, we hit it off personally – he accepted my na€ıve notions
about producing vaccines in plants and tempered the ideas with
sound experimental planning. He was also willing to create a
team with me, and live through early years of financial uncer-
tainty as we tried to capture funding for PMP research – a
concept that grant panels found somewhat zany at the time. Our
team has moved among three separate academic institutions over
the last 25 years, and we have jointly written a large number of
grant proposals and publications. I am very grateful for his
continued friendship and collegiality.
Achieving HBsAg expression in plants in 1992 was our first joint
publishable success (Mason et al., 1992). Hugh and I were
delighted to see that the antigen we recovered from transgenic
plants was organized as virus-like particles (VLP), which had the
same properties as the antigen in the yeast-produced hepatitis B
vaccine (Figure 1). While this may seem unsurprising today, it was
a key step for us in convincing a skeptical vaccine research
community of the PMP concept. In the next few years, we also
created transgenic plants that expressed other antigens, including
the binding subunit of E. coli enterotoxin (LTB) and the capsid
protein of norovirus genotype 1 (or Norwalk virus, as it was
known then) which formed virus-like particles (NV-VLP). Another
necessary step for gaining credibility for PMP was to show that
oral delivery of tissue from transgenic plants would induce an
immune response. In a series of publications, we reported that
feeding “animals” plant tissue expressing HBsAg, LTB or NV-VLP
would induce antigen-specific antibodies. Using these data, we
filed Investigational New Drug (IND) applications with the U.S.
Food and Drug Administration (FDA) and gained approval for
three human clinical trials. In all cases, the volunteers ate raw
potato tubers peeled and cut into bite-sized chunks, and in all
cases, we saw antibody responses indicating mucosal immuniza-
tion (Arntzen et al., 2005).
In 2004, I was delighted to help organize a scientific confer-
ence on PMP, supported by the Fondation Merieux and held in
Veyrier-du-Lac, France. I believe this was the first time that an
(a)
(b)
Figure 1 We used electron microscopy and immunocytochemistry to
demonstrate that HBsAg accumulated in plant tissue as either tubular
structures or virus-like particles (Smith et al., 2003). (a) In this electron
micrograph, arrows indicate dilated portions of rough endoplasmic
reticulum (RER) containing circular particles or cross sections of tubular
structures. (b) Enlargement of the RER. (N = Nucleus; Cp = Chloroplast;
Mb = Microbody) (Thanks to Lizabeth Richter for these electron
micrographs.).
ª 2015 The Authors. Plant Biotechnology Journal published by Society for Experimental Biology and The Association of Applied Biologists and John Wiley & Sons Ltd., 13, 1013–1016
Charles Arntzen1014
international group had assembled to discuss ‘Plant-Derived
Vaccines and Antibodies: Potential and Limitations’. We noted
that in the decade following our initial 1992 publication, at least
100 publications on the subject of plant-derived vaccines were in
journals, describing at least 45 antigens produced in plants. In a
summary figure from that meeting (Arntzen et al., 2005) we
identified three research strategies then in use: transgenic plants
with stable expression of genes in the nucleus, or in the
chloroplast genome, and transient expression using virus-derived
vectors. The overriding focus of the time was on transgenic
plants. The only nod given to transient expression was modified
viruses, such as tobacco mosaic viruses that could infect plants
and produce virions with epitope fusions to the coat protein. In
that context, it is amazing that a decade later international
meetings such as PBVAB-15 (held in June of 2015 in Switzerland)
are dominated by protein expression using Agrobacterium-
mediated transient expression, and deconstructed viral genomes
delivered via Agrobacterium (Agro) to plant leaves (see the superb
review on this subject by G. Lomonossoff and H. Peyret in this
volume). Although the research relating to Agro-delivered
reconstructed viral genomes had started in 2004, it was too
immature to be treated as something necessary to include in a
conference! Seeing where that area is today emphasizes the
beauty of ‘disruptive technical innovation’.
In 1992, my research concept had been entirely focused on
low-cost vaccines for oral delivery in the developing world, and
for the next several years, I actively promoted the idea of ‘edible
vaccines’ (Figure 2). As I have said in recent years that may have
attracted attention in the plant biology realm, but it probably has
been much more counterproductive in the traditional vaccine
industry. I have come to regret coining the term. In my naivete, I
was ignoring the rigorous regulatory requirements that govern-
ment agencies and the vaccine industry follow to give us today’s
highly effective and wonderfully safe vaccines. I still believe that
using plant tissue for low-cost delivery of unpurified (or partially
purified) antigens, perhaps as a dry powder, is technically feasible
for mucosal vaccination. I see progress in this direction for animal
vaccines, which is needed. However, plant-to-plant variations will
require careful (and expensive) analytical controls to determine
exact dosages of antigen if it is not purified. As we noted in 2004,
‘While it was frequently mentioned that plant-based protein
production is highly cost effective, participants at the conference
were reminded that production costs may represent only a small
part of the cost of a vaccine. GMP (Good Manufacturing Practice)
requirements, purification, quality controls for vaccine approval
are major cost factors in (human) vaccine production (Arntzen
et al., 2005)’. My ‘edible vaccine’ notion also had an unspecified
need for high levels of antigen accumulation in plant tissues to
ensure that only a small amount of plant tissue would be needed
to deliver one dose of vaccine. This issue has been addressed in
chloroplast transformation systems (see the excellent commen-
tary on this topic by K-C Kwon and H. Daniell in this volume), but
current deconstructed viral systems delivered by Agro have
shown orders of magnitude higher antigen accumulation than
we could achieve in transgenic plants with nuclear gene insertion.
By 2015, I have come to appreciate that the costs of purifying an
antigen (or antibody or human enzyme) may not be an
impediment to development of a new vaccine or drug if the
desired protein is produced at high levels in plant tissue.
Additionally, purified antigens can follow the regulatory path-
ways now well established for subunit vaccines or other protein
drugs.
The recent past and looking ahead
In 1997, I joined the Advisory Board of the ‘Agbio Capital’ venture
capital fund. We listened to many business plan presentations,
but one particular plan had a great impact on me. It was by Dr.
Yuri Gleba, who had founded ICON Genetics AG in Halle,
Germany in 1999. He described ‘deconstructed viral vectors’
which could be delivered by Agro infiltration into plant leaves. In
my view, it was the ‘disruptive technology’ that the PMP field
needed. But the board did not approve funding for ICON because
they thought it was ‘a platform technology that needed a product
focus’. After determining that it would not be a conflict of
interest, I made personal contact with Dr. Gleba (or Yuri as most
of us call him) to discuss collaboration. He agreed, and Luca Santi
travelled from our ASU laboratory to Germany to work for a few
months with the ICON scientists. Besides bringing additional viral
vector skills back to our team in Arizona, this lead to our first ASU/
ICON collaborative publication relating to a Yersinia pestis
biothreat vaccine that protected animal models (Santi et al.,
2006).
For the last 14 years, since moving to ASU, my major
contribution to science has been in the design and management
of multidisciplinary and multicomponent projects, especially
those that link academia and industry. It has been highly
rewarding to see the emergence of PMP-based companies begin
commercial introduction of products. The success of Protalix
Biotherapeutics in gaining FDA approval for an enzyme thera-
peutic for human use was a milestone for the field, and ongoing
product introduction by them, and by Medicago and Ventria (just
to name two of the larger efforts) and others will ensure the
successful future of the PMP field.
As for me, I will return this discussion to ZMapp, which I used
to introduce this manuscript. Although I have only played a small
role in the development of the product, it is incredibly rewarding
Figure 2 In the 1990s, we expressed antigens in multiple crop species
with a goal of creating a minimally processed oral vaccine. The concept of
using banana fruit attracted extensive interest in the press, although the
low expression of antigen in the fruit, and the 3 + year cycle needed to
create a transgenic fruiting plant caused us to abandon this area of
research. (Photograph from the Boyce Thompson Institute files, 1999).
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to see that something that started as a hypothesis has actually
been used in life-saving treatments. I have been fortunate to work
with a wonderful team of people at ASU, and with companies
with extraordinary and complementary skills – and especially
Mapp, ICON, and KBP. I am not yet ready to quit, as I believe that
a plant-made norovirus vaccine will only come if we can find a
formulation that will work as a robust mucosal vaccine (Velasquez
et al., 2011). And, we have ongoing research with that goal in
mind.
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